Phase 2 Endometrial Cancer Trial, Recruiting NCT07407647 Sponsor: Ohio State University Comprehensive Cancer Center Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 2 Endometrial Cancer Trial, Recruiting

NCT07407647
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have anal, rectal, cervical, vaginal, or vulvar cancer and are receiving radiation treatment aimed at curing the cancer (either radiation alone, or radiation combined with internal radiation called brachytherapy)
  • People who are receiving or have previously received chemotherapy alongside their cancer treatment
  • People who have had previous surgery on the female reproductive organs
  • People who have had rectal surgery (including certain bowel-related operations)
  • People who are menopausal, meaning either they are over 50 and have not had a period for 12 months, or they have had both ovaries removed

Who may not be able to join:

  • People who have scleroderma, mixed connective tissue disorder, or lupus (certain immune system or connective tissue conditions)
  • People who have previously received radiation treatment to the pelvic area
  • People who have unexplained abnormal genital bleeding that is not related to their current cancer or its treatment
  • People who have cancer or abnormal thickening of the uterine lining (endometrial cancer or endometrial hyperplasia)
  • People who have used certain hormone therapies recently — specifically, injectable estrogen-only or progestin implant therapies within the past 3 months before joining the study
  • People who have used estrogen pellets or injectable progestin within the past 6 months before joining the study
  • People who have used estrogen, progestin, or DHEA taken by mouth, or a hormone-releasing intrauterine device, within the past 8 weeks before joining the study
  • People who have used vaginal estrogen products (rings, creams, tablets, or gels), estrogen skin patches, vaginal hyaluronic acid, or herbal treatments that act like estrogen (such as black cohosh) within the past 4 weeks before joining the study
  • People with a history of breast cancer
  • People who are receiving radiation treatment for palliative (comfort-focused) care rather than curative treatment
  • People who do not meet the criteria for menopause as defined by the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Allison M Quick, MD, Ohio State University Comprehensive Cancer Center

Phone: 800-293-5066

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Ohio State University Comprehensive Cancer Center
Registry
ClinicalTrials.gov
Start date
12 March 2026
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of grade 2 or higher adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov